Nebulised drugs in palliative care

Thorax

Volumn 52, Issue SUPPL. 2, 1997, Pages

  Ahmedzai, S ^a   Davis, C ^b  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b Countess Mountbatten House ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BRONCHODILATING AGENT; BUDESONIDE; BUPIVACAINE; DIAMORPHINE; FENTANYL; LIDOCAINE; LOCAL ANESTHETIC AGENT; MORPHINE; MORPHINE SULFATE; MUCOLYTIC AGENT; OPIATE AGONIST; SALBUTAMOL; SODIUM CHLORIDE; TERBUTALINE;

AIRWAY OBSTRUCTION; CLINICAL TRIAL; COUGHING; DRUG BIOAVAILABILITY; DYSPNEA; GOOD CLINICAL PRACTICE; HOME CARE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MEDICAL NEBULIZER; NEBULIZATION; ORAL DRUG ADMINISTRATION; PAIN; PALLIATIVE THERAPY; PARTICLE SIZE; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030962412     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.52.2008.s75     Document Type: Review

References (14)

1. Ahmedzai S. Palliation of respiratory symptoms. In: Doyle D, Hanks GW, MacDonald N, eds. Oxford textbook of palliative medicine. Oxford: Oxford University Press, 1993: 349-78.
2. Winning AJ, Hamilton RD, Guz A. Ventilation and breathlessness on maximal exercise in patients with interstitial lung disease after local anaesthetic aerosol inhalation. Clin Sci 1988;74:275-81.
3. Stark RD, O'Neill PA, Russell NJW, Heapy CG, Stretton TB. Effects of small-particle aerosols of local anaesthetic on dyspnoea in patients with respiratory disease. Clin Sci 1985;69:29-36.
4. Winning AJ, Hamilton RD, Shea SA, Knott C, Guz A. The effect of airway anaesthesia on the control of breathing and the sensation of breathlessness in man. Clin Sci 1985; 68:215-25.
5. Wilcock A, Corcoran R, Tattersfield AE. Safety and efficacy of nebulised lignocaine in patients with cancer and breathlessness. Palliat Med 1994;8:35-8.
6. Howard P, Clayton RM, Brennan SR, et al. Lignocaine aerosol and persistent cough. Br J Dis Chest 1977;71: 19-24.
7. Young IH, Daviskas E, Keena VA. Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease. Thorax 1989;44:387-90.
8. Beauford W, Saylor TT, Stansbury DW, Avaolos K, Light RW. Effects of nebulised morphine sulfate on the exercise tolerance of the ventilatory limited COPD patient. Chest 1993;104:175-8.
9. Masood AR, Reed JW, Thomas SHC. Lack of effect of inhaled morphine on exercise-induced breathlessness in chronic obstructive pulmonary disease. Thorax 1995;50: 629-34.
10. Davis CL, Penn K, R A'Hern, Daniels J, Slevin M. Single dose randomised controlled trial of nebulised morphine in patients with cancer-related breathlessness. Palliat Med 1996;10:64-5A.
11. Farncombe M, Cater S, Gillin A. The use of nebulised opioids for breathlessness: a chart review. Palliat Med 1994;8:306-12.
12. Master N, Heap G, Wedly J, Moore A. Inhaled nebulised morphine and diamorphine: useful in general practice? Practitioner 1988;2:910-4.
13. Chrubasik J, Wust H, Friedrich G, Geller G. Absorption and bioavailability of nebulised morphine. Br J Anaesth 1988;61:228-30.
14. Davis CL, Lam W, Roberts M, Daniels J, Joel SP, Slevin ML. The pharmacokinetics of nebulised morphine. Proceedings of International Association for the Study of Pain. Seattle: IASP Publications, 1993: 379 (abstract 995).